¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Human T-lymphotropic virus type III"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • parthenogenetic type
    ´Ü¼º»ý½ÄÇü
  • split-electrode-type probe
    ºÐÇÒÀü±Ø´õµëÀÚ
  • sthenic type
    ±Ù·ÂÇü
  • storage-type
    ÃàÀûÇü
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü
  • simple type schizophrenia
    ´Ü¼øÇüÁ¤½ÅºÐ¿­º´
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • wild type
    ¾ß»ýÇü
  • wild type strain
    ¾ß»ýÁÖ
  • attenuated virus
    ¾àµ¶È­¹ÙÀÌ·¯½º
  • avian neurolymphomatosis virus
    Á¶·ù½Å°æ¸²ÇÁÁ¾Áõ¹ÙÀÌ·¯½º
  • adeno-associated satellite virus
    ¾Æµ¥³ë°ü·ÃÀ§¼º¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • type culture
    Ç¥ÁرÕÁ¾
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î
  • disorganized type schizophrenia
    ºØ±«Á¤½ÅºÐ¿­º´
  • dromedary type
    ´ÜºÀÇü
  • dysplastic type
    Çü¼ºÀÌ»óÇü
  • expansive type
    °ú´ëÇü
  • extroverted type
    ¿ÜÇâÇü
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • hebephrenic type schizophrenia
    ÆÄ°úÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • human thyroid stimulating hormone =HTSH
    »ç¶÷°©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • identification by isolated human tooth
    Ä¡Á¾°¨º°(öÍðúÊüܬ).
  • radioactive iodine labeled human serum albumin
    ¹æ»ç¼º ¿ä¿ÀµåÇ¥ÁöÀÎÇ÷û(¡­ øöãÛìÑúìôè)¾ËºÎ¹Î.
  • C type particle
    CÇüÀÔÀÚ
  • C-type particle
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • Charcot-Marie type
    »þ¸£ÄÚ-¸¶¸®Çü.
  • Duchenne-Landouzy type
    µÚ½Ã¿£´À-¶õµÎ¿ìÁöÇü.
  • Gougerot-Ruiter type vasculitis
    ±¸Á¦·Î ·çÀÌÅÍ Çü Ç÷°ü¿°
  • L-type chnnels
    L-Çü Åë·Î(÷×ÖØ)
  • Lafora body type of myoclonus
    ¶óÆ÷¶ó üÇü ¸¶ÀÌ¿ÀŬ·Î´©½º.
  • Lutheran s type
    ·çÅ×¶õÇü.
  • Mobitz type I SA block
    ¸ðºñÃ÷ ¥°Çü µ¿¹æÂ÷´Ü.
  • Mobitz type II AV block
    ¸ðºñÃ÷ ¥±Çü ¹æ½ÇÂ÷´Ü.
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • human dynamics
    Àΰ£°øÇÐ.
  • human engineering =ergonomics
    Àΰ£°øÇÐ.
  • human fetal membranes
    »ç¶÷žƸ·
  • human genetics
    ÀηùÀ¯ÀüÇÐ.
  • human genome
    Àΰ£ °Ô³ð
  • human genome project
  • human herpesvirus 6 infection
  • human histocompatibility antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø.
  • human histocompatibility antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø.
  • human identification
    °³Àνĺ°.
  • human leukocyte antigen
    Àΰ£ ¹éÇ÷±¸ Ç׿ø
  • human leukocyte antigen
    ÀÎü¹éÇ÷±¸Ç׿ø.
  • human leukocyte antigen
    ÀÎü¹éÇ÷±¸Ç׿ø.
  • human leukocyte antigen
    ÀÎü¹éÇ÷±¸Ç׿ø.
  • human leukocyte antigen (HLA) complex
    »ç¶÷ ¹éÇ÷±¸Ç׿øº¹ÇÕü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • replication-defective virus
    º¹Á¦ºÒ´É(ÝÕÒö) ¹ÙÀÌ·¯½º
  • Rous sarcoma virus
    ¶ó¿ì½º À°Á¾(ë¿ðþ) ¹ÙÀÌ·¯½º
  • sendai virus
    ¼¾´ÙÀÌ ¹ÙÀÌ·¯½º
  • simian virus 40
    ½Ã¹Ì¾È ¹ÙÀÌ·¯½º40
  • slow virus
    ½½·Î ¹ÙÀÌ·¯½º
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
  • virus
    ¹ÙÀÌ·¯½º
  • virus antigen
    ¹ÙÀÌ·¯½º Ç׿ø (ù÷ê«)
  • virus receptor
    ¹ÙÀÌ·¯½º ¼ö¿ëü (â¥é»ô÷)
  • virus theory of cancer
    ¹ÙÀÌ·¯½º ¾Ï¹ß»ý·Ð(äßÛ¡ßæÖå)
  • xenotropic virus
    Ä£(öÑ)ÀÌÁ¾(ì¶ðú) ¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MLF Median Longitudinal Fasciculus
  Role; links the CN III Nucleus with Contralateral CN ...
NYHA New York Heart Association
  Heart Disease¿¡ ´ëÇÑ Functional Classification
 &nbs...
AI, AII, AIII angiotensin I, II, III
CIN 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ)
CONPA-DRI III conpa-dri I plus intensified doxorubicin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
JH III Juvenile hormone III
pol III Polymerase III
P-III-P precollagen-III-peptide
PDE III phosphodiesterase III
URO-III-S uroporphyrinogen III synthase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • hutchinson-type neuroblastoma
    ÇãÄ£½¼Çü ½Å°æ¸ð¼¼Æ÷Á¾
  • hypocalcified type
    ¼®È¸È­ ºÎÀüÇü
  • immediate-type
    Áï½ÃÇü
  • intracanalicular type
    ¼Ò°ü³» Çü
  • iris-type
    ȫä ¸ð¾ç
  • Jaeger's test type
    ¿¹°Å ¹®ÀÚ
    ½Ã·Â °Ë»ç¿¡ »ç¿ëµÇ´Â ´ë¼ÒÀÇ ¹®ÀÚ¸¦ ´Ã¾î³õÀº Ç¥.
  • jealous type
    ÁúÅõÇü
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
  • major type
    ÁÖµÈ ÇüÅÂ
  • membrane type
    ¸·Çü
  • mesial step type
    ±Ù½É °è´ÜÇü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
mucolipidosis III <biochemistry> Mucolipidosis with mild Hurler-like symptoms, restricted joint mobility, short stature, mild mental retardation, and dysplastic skeletal changes, especially of the hip. Aortic and mitral valve disease are often present.
It is associated with a deficiency of UDP-N-acetyl glucosamine and lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase.
Inheritance: autosomal recessive.
Synonym: pseudo-Hurler polydystrophy, pseudopolydystrophy.
(05 Mar 2000)
mucopolysaccharidosis III Mucopolysaccharidosis characterised by heparitin sulfate in the urine, progressive mental retardation, mild dwarfism, and other skeletal disorders. There are four clinically indistinguishable but biochemically distinct forms, each due to a deficiency of a different enzyme.
(12 Dec 1998)
congenital antithrombin III deficiency Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait.
Inheritance: autosomal dominant.
(27 Sep 1997)
connective tissue activating peptide III Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
mycinamicin III O-methyltransferase <enzyme> Catalyses the incorporation of the methyl group of s-adenosyl-l-methionine at the 3'' position of mycinamicin III; from micromonospora griseorubida; genbank d16097
Registry number: EC 2.1.1.-
Synonym: mycf gene product, miii o-mtase
(26 Jun 1999)
cranial mononeuropathy III (compression type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III. Damage is usually caused by compression of the nerves from localised lesions or a swelling in the area of the nerve.
Examples include cerebral aneurysms and tumours Symptoms include a drooping eyelid and double vision.
(diabetic type) A disorder involving vision changes and eyelid drooping associated with a decreased functioning of cranial nerve III as a complication of diabetes.
Symptoms include a drooping eyelid and double vision. Good control of blood sugars can reduce the incidence of this complication.
(27 Sep 1997)
cranial nerve III <anatomy, nerve> The occulomotor nerve is responsible for motor enervation of upper eyelid muscle, extraocular muscle and pupillary muscle.
Lesions of the oculomotor nerve results in ptosis (dropping eyelid), deviation of the eyeball outward, double vision and a dilated pupil.
Synonym: cranial nerve III.
(27 Sep 1997)
processus styloideus ossis metacarpalis III A pointed projection from the dorsolateral angle of the base of the third metacarpal bone; it sometimes exists as a separate ossicle.
Synonym: processus styloideus ossis metacarpalis III.
(05 Mar 2000)
Hind III <enzyme, molecular biology> Commonly used type II restriction endonuclease isolated from Haemophilus influenzae, it cleaves the sequence AAGCTT between the two As thus generating sticky ends.
(18 Nov 1997)
HTLV-III <abbreviation> Human T-cell lymphotropic virus type III.
See: human immunodeficiency virus.
(05 Mar 2000)
NADH-Fe(III)EDTA oxidoreductase <enzyme> From cryptococcus albidus; catalyses the formation of nad+ and fe(ii)edta from NADH and fe(iii)edta; forms ethylene from 2-oxo-4-methylthiobutyric acid
Registry number: EC 1.6.99.-
(26 Jun 1999)
Sudan III A red stain, (C6H5)N==N(C6H4)N==N(C10H6)OH, used for neutral fat in histologic technique; it also stains the fatty envelope of the tubercle bacillus.
Synonym: Sudan red III.
(05 Mar 2000)
Sudan red III A red stain, (C6H5)N==N(C6H4)N==N(C10H6)OH, used for neutral fat in histologic technique; it also stains the fatty envelope of the tubercle bacillus.
Synonym: Sudan red III.
(05 Mar 2000)
DNA polymerase III <enzyme> An enzyme that aids in DNA replication. It has a number of different functions, such as: proofreading newly replicated DNA, removing nucleotides from the 3' end of the strand one by one, and binding nucleotides from the 5' end of the strand.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á